Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Venlafaxine-XR Clear all
Completed Not applicable Interventional

Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury

NCT00167856
View directory record Official record
Conditions
Neuropathic Pain, Pain, Spinal Cord Injuries
Interventions
Venalafaxine hydrochloride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927
View directory record Official record
Conditions
Bipolar Type II Disorder
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
Stanley Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2008 · Synced Sep 29, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine XR, Placebo, JNJ26489112
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Arcadia, California • Escondido, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 29, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

NCT03274817
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

NCT00186264
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
venlafaxine XR, hydrocortisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

NCT00854100
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

NCT00742573
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Psychosocial and Medication Treatment for Anxiety in Alcoholism

NCT00248612
View directory record Official record
Conditions
Alcohol-Related Disorders, Anxiety Disorders
Interventions
Venlafaxine, CBT, Progressive muscle relaxation therapy (PMR), Placebo medication
Drug · Behavioral · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

NCT00183274
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Venlafaxine XR, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Combined Treatment for Generalized Anxiety Disorder (GAD)

NCT00620776
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cognitive Behavioral Therapy, Venlafaxine XR
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

NCT00200902
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Placebo, Interpersonal Clinical Interaction (ICI)
Drug · Other · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy

NCT03574792
View directory record Official record
Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 29, 2026, 2:12 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

International Study to Predict Optimised Treatment - in Depression

NCT00693849
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Sertraline, Venlafaxine-XR
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
13
States / cities
Colton, California • Mission Viejo, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression

NCT00177528
View directory record Official record
Conditions
Depression
Interventions
venlafaxine-XR
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

NCT02977299
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

NCT00735670
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Venlafaxine HCl, Placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 4 Interventional Results available

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg, Referral to Psychiatry, Survey only
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 29, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

NCT00564278
View directory record Official record
Conditions
Depression
Interventions
Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 29, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 29, 2026, 2:12 PM EDT